Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › ASND
RICE HALL JAMES & ASSOCIATES, LLC position in ASND
ASCENDIS PHARMA A/S · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 145,275 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$33.1M, representing 1.75% of its reported portfolio and ranking #12 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's ASND position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in ASND in Q3 2023 at 169,787 shares (US$15.9M). The position peaked in Q2 2026 at 148,644 shares, worth US$39.6M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 145,275 shares valued at US$33.1M — a reduction of -3,369 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 169.79K | $15.90M | New |
| Q4 2023 | 168.88K | $21.27M | Reduce |
| Q1 2024 | 162.41K | $24.55M | Reduce |
| Q2 2024 | 151.66K | $20.68M | Reduce |
| Q3 2024 | 160.61K | $23.98M | Add |
| Q4 2024 | 163.89K | $22.56M | Add |
| Q1 2025 | 160.80K | $25.06M | Reduce |
| Q2 2025 | 160.11K | $27.63M | Hold |
| Q3 2025 | 147.09K | $29.24M | Reduce |
| Q4 2025 | 145.05K | $30.93M | Reduce |
| Q1 2026 | 148.39K | $33.94M | Add |
| Q2 2026 | 148.64K | $39.65M | Hold |
| Q3 2026 | 145.28K | $33.10M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ASND and 13F data
ASND (ASCENDIS PHARMA A/S) is a Health Care company. 36 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), WESTFIELD CAPITAL MANAGEMENT CO LP (US$1.17B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ASND
- RA CAPITAL MANAGEMENT, L.P. 10.28M sh · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M sh · $1.80B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 5.13M sh · $1.17B · Q3 2026
- Avoro Capital Advisors LLC 5.05M sh · $1.15B · Q3 2026
- Jupiter Topco LLC 3.65M sh · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.08M sh · $474.58M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.16M sh · $310.39M · Q2 2026
- Vestal Point Capital, LP 375.00K sh · $100.02M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K sh · $65.20M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K sh · $60.05M · Q2 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held ASND?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in ASND?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 145.28K shares of ASND (ASCENDIS PHARMA A/S), valued at $33.10M, representing 1.75% of its reported portfolio and ranking #12.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling ASND?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in ASND. The position peaked in Q2 2026 at 148.64K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., WESTFIELD CAPITAL MANAGEMENT CO LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.